Table 1 Subject demographics.

From: Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients

Characteristic

MS participant (n = 24)

Control (n = 24)

Age range (yrs)

40.7 ± 8.5

43.3 ± 16.4

EDSS

2.4 ± 1.3

 

Disease duration (yrs)

9.3 ± 6.6

 

Treatment (n)

  

  • Naïve

1

 

  • OFF > 3 months

4

 

  • Interferon beta-1b

2

 

  • Interferon beta-1a

3

 

  • Glatiramer acetate

2

 

  • Natalizumab

4

 

  • Fingolimod

8

 
Back to article page